Genetic knockout and pharmacologic inhibition of neuronal nitric oxide synthase attenuate nerve injury-induced mechanical hypersensitivity in mice
© Guan et al; licensee BioMed Central Ltd. 2007
Received: 01 August 2007
Accepted: 08 October 2007
Published: 08 October 2007
Neuronal nitric oxide synthase (nNOS) is a key enzyme for nitric oxide production in neuronal tissues and contributes to the spinal central sensitization in inflammatory pain. However, the role of nNOS in neuropathic pain remains unclear. The present study combined a genetic strategy with a pharmacologic approach to examine the effects of genetic knockout and pharmacologic inhibition of nNOS on neuropathic pain induced by unilateral fifth lumbar spinal nerve injury in mice. In contrast to wildtype mice, nNOS knockout mice failed to display nerve injury-induced mechanical hypersensitivity. Furthermore, either intraperitoneal (100 mg/kg) or intrathecal (30 μg/5 μl) administration of L-NG-nitro-arginine methyl ester, a nonspecific NOS inhibitor, significantly reversed nerve injury-induced mechanical hypersensitivity on day 7 post-nerve injury in wildtype mice. Intrathecal injection of 7-nitroindazole (8.15 μg/5 μl), a selective nNOS inhibitor, also dramatically attenuated nerve injury-induced mechanical hypersensitivity. Western blot analysis showed that the expression of nNOS protein was significantly increased in ipsilateral L5 dorsal root ganglion but not in ipsilateral L5 lumbar spinal cord on day 7 post-nerve injury. The expression of inducible NOS and endothelial NOS proteins was not markedly altered after nerve injury in either the dorsal root ganglion or spinal cord. Our findings suggest that nNOS, especially in the dorsal root ganglion, may participate in the development and/or maintenance of mechanical hypersensitivity after nerve injury.
Considerable evidence has shown that nitric oxide (NO) acts as an important mediator in the peripheral and central nervous systems and functions in a wide variety of physiologic and pathophysiologic processes, such as neurotransmission, synaptic plasticity, neuroprotection, neurotoxicity, and pathologic pain [1–3]. NO is synthesized by three well-characterized isoforms of NO synthase (NOS): neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Under pathologic conditions, these three NOS isoforms could be upregulated in nervous tissues [4–6]. Thus, the pathophysiologic functions of NO in the nervous system may be regulated by the expression and activity of one, two, or all three NOS isoforms.
Neuronal NOS is expressed in the neurons and produces predominantly NO in neuronal tissues . The contribution of nNOS-synthesized NO to nociceptive processing has been characterized in several inflammatory pain models . Peripheral inflammation induced by formalin or complete Freund's adjuvant increases nNOS (but not eNOS or iNOS) expression in the spinal cord [5, 7, 8] and dorsal root ganglion (DRG) . Systemic or intrathecal administration of nonspecific NOS inhibitors or selective nNOS inhibitors reduces the exaggerated pain in animals after formalin-, carrageenan-, or complete Freund's adjuvant-induced peripheral inflammation [5, 9–15]. Moreover, targeted disruption of the nNOS gene attenuates carrageenan- and complete Freund's adjuvant-induced thermal and mechanical pain hypersensitivity in mice [5, 15], although nNOS knockout mice were reported to display intact formalin-induced nociceptive behaviors . These observations indicate that nNOS at the spinal cord level may play a critical role in the central mechanism of inflammatory pain.
In addition to inflammation, peripheral nerve injury also causes clinically relevant persistent or chronic pain. Although nerve injury-induced neuropathic pain has some unique characteristics in regard to pathogenesis, central mechanisms, and treatment compared to inflammatory pain , these two types of persistent pain may share some intracellular signaling pathways in their central mechanisms . However, the exact role of nNOS in neuropathic pain, especially at the spinal cord level, is unclear. Peripheral nerve injury increased expression of both mRNA and protein for nNOS in the DRG, but not in spinal cord [19–22]. Although systemic or spinal treatment with specific and nonspecific nNOS inhibitors has been shown to block neuropathic pain [23–27], two investigators reported that systemic or intrathecal administration of specific and nonspecific nNOS inhibitors had no effect on nerve injury-induced allodynia [19, 28]. It is evident that these pharmacologic results are conflicting. In the current study, by combining a genetic strategy (using nNOS knockout mice) with a pharmacologic approach (using selective and nonspecific nNOS inhibitors), we determined the functional role of nNOS in chronic neuropathic pain induced by L5 spinal nerve injury in mice. In addition, we examined the expression of nNOS, as well as iNOS and eNOS, in DRG and spinal cord after spinal nerve injury.
Effect of nNOS knockout on spinal nerve injury-induced mechanical hypersensitivity
Effect of systemic administration of a nonspecific NOS inhibitor on nerve injury-induced mechanical hypersensitivity
Effect of intrathecal injection of nonspecific and specific nNOS inhibitors on nerve injury-induced mechanical hypersensitivity
Effect of spinal nerve injury on nNOS expression in the DRG and spinal cord
The present study provides the first evidence that targeted disruption of the nNOS gene significantly attenuates nerve injury-induced mechanical hypersensitivity. Moreover, nerve injury-induced mechanical hypersensitivity in WT mice was significantly inhibited by systemic and intrathecal administration of L-NAME and by intrathecal treatment with 7-NI. Peripheral nerve injury increased the expression of nNOS in the DRG, although it did not alter the expression of nNOS in the spinal cord. Our findings suggest that nNOS, especially in the DRG, may play a critical role in nerve injury-induced mechanical hypersensitivity.
Conflicting pharmacological evidence has been reported regarding the effects of systemic or spinal treatment with specific or non-specific NOS inhibitors on neuropathic pain. Meller et al.  first reported that intrathecal administration of L-NAME (20 nmol) on day 3 after loose ligation of the sciatic nerve blocked the thermal hyperalgesia in rats for a period of 2 h. A subsequent study also demonstrated that injecting 3-bromo-7-NI (a specific nNOS inhibitor, 10 mg/kg) intramuscularly into the mid-thigh region daily for 7 days beginning on day 7 post-surgery significantly alleviated nerve injury-induced thermal hyperalgesia from weeks 5 and 6 onward in rats . Yoon et al.  further showed that both mechanical and cold allodynia induced by tight ligature of the left L5 and L6 spinal nerves were dose dependently suppressed during the maintenance phases (1 to 3 weeks post-ligature) by intraperitoneal L-NAME (10, 50, 100, and 200 μM/kg). In support of these findings, our pharmacological study showed that spinal nerve injury-induced mechanical hypersensitivity in mice could be dramatically attenuated by systemically (100 mg/kg) and intrathecally (30 μg) injected L-NAME and by intrathecally injected 7-NI (8.15 μg) on day 7 post-nerve injury (Figs. 2, 3, 4). Interestingly, Yamamoto and Shimoyama  found that the development of thermal hyperesthesia evoked by sciatic nerve constriction injury was significantly delayed by intrathecal pre-treatment (10 min before injury), but not post-treatment (15 min after injury), with NOS inhibitors Nω-nitro-L-arginine (30 μg) and L-NAME (100 μg). However, Pan et al.  reported that allodynia induced by tight ligation of the left L5 and L6 spinal nerves was not affected by intrathecal injection of either NG-monomethyl-arginine (a non-specific NOS inhibitor, 30 μg) or 1-(2-trifluoromethylphenyl) imidazole (a nNOS inhibitor, 30 μg) at the third or fourth week post-nerve injury. Additionally, Luo et al.  observed that neither pre-surgical (once daily for 6 days beginning 30 min before surgery) nor post-surgical (days 11 through 13) 7-NI (50 mg/kg) given subcutaneously or intraperitoneally affected the development or maintenance of tactile allodynia evoked by tight ligature of the left L5 and L6 spinal nerves in rats. The reason for the discrepancies among these pharmacological studies is unclear but may be related to the drug potency, delivery method, dose, and administration times. It is worth noting that only one dose of a nonspecific or specific nNOS inhibitor was administered by Luo et al.  and Pan et al . It is possible that the higher doses used in these two studies might have had a significant inhibitory effect on nerve injury-induced neuropathic pain. Our nNOS knockout mouse study clearly demonstrated that deficiency of nNOS significantly blunted spinal nerve injury-induced mechanical hypersensitivity (Fig. 1). In addition, nNOS knockout mice exhibited impaired nerve injury-induced thermal hypersensitivity (data not shown). Although it has been reported that spinal eNOS is upregulated in nNOS KO mice , it appears that this upregulation does not fully compensate for nNOS function in neuropathic pain. Thus, our genetic knockout and pharmacologic studies support the notion that nNOS, particularly at the spinal cord level, may contribute to the mechanisms that underlie the development and/or maintenance of neuropathic pain.
Peripheral nerve injury insult has distinct effects on nNOS expression in the DRG and dorsal horn. Under normal conditions, the DRG contains only a few neurons that exhibit nNOS labeling, the majority of which are very small, whereas spinal dorsal horn exhibits intense nNOS labeling in several neuronal types, especially in the superficial dorsal horn . It has been reported that constriction of the common sciatic nerve in rats increased nNOS expression in the ipsilateral L4-L6 DRG, but not in spinal segments L4-L6 . The increased level of nNOS protein in the DRG was seen in the small, medium, and large cell bodies . Likewise, tight, unilateral ligature of the rat L5 and L6 spinal nerves increased nNOS mRNA in ipsilateral L5/6 DRG neurons, but not in dorsal horn, beginning 1 day after nerve ligation and lasting for at least 13 weeks . A corresponding increase in DRG (but not spinal cord) nNOS protein was also observed and localized mainly to small and occasionally medium-sized sensory neurons [19, 21]. Consistent with these findings in rats, our study showed that unilateral injury of the fifth spinal nerve in mice also increased expression of nNOS protein in the ipsilateral fifth DRG, but not in dorsal horn. An increase in the DRG NOS catalytic activity and a decrease in spinal NOS catalytic activity have been reported following peripheral nerve injury [20, 22]. The evidence described above indicates that peripheral nerve injury up-regulates expression and activity of nNOS in small DRG neurons and down-regulates its expression and activity in the spinal cord. Such adaptations suggest that the increased nNOS in the DRG may be involved in the mechanism underlying the development and/or maintenance of neuropathic pain. It has been demonstrated that intrathecally administered agents can directly affect activities of DRG proteins in pain processing in addition to affecting activities of these proteins in spinal cord neurons . It is very likely that the pharmacologic effects of specific and non-specific NOS inhibitors in the present study were mediated through their actions on the DRG nNOS, although our data could not exclude their effects on spinal cord nNOS.
Consistent with previous reports [5, 31, 32], our study detected basal expression of eNOS and iNOS proteins in the spinal cord and DRG of mice under normal conditions. However, the expression of neither was altered in the spinal cord or DRG on day 7 post-nerve injury. It should be noted that we did not examine iNOS expression at the ligature site or at other time points post-nerve injury. Previous studies showed that local expression of iNOS was induced at 3 days and persisted for at least 26 days at the constriction and distal sites following chronic constriction partial nerve injury [33–36]. Systemic and topical administration of specific or non-specific iNOS inhibitors reversed nerve hyperaemia proximal and distal to the constriction . Targeted disruption of the iNOS gene slowed Wallerian degeneration of myelinated fibers and delayed regeneration of myelinated and smaller caliber fibers in a chronic constriction partial nerve injury model . Slowed nerve degeneration is associated with normal initiation but delayed expression of neuropathic pain , suggesting that local induction of iNOS expression may be important in the pathogenesis of nerve injury-induced neuropathic pain. Thus, our data do not exclude the possibility that iNOS at the ligature site might play a role in the development of neuropathic pain.
The mechanism by which DRG NOS-synthesized NO contributes to the development and/or maintenance of neuropathic pain is unclear. A gaseous molecular, NO diffuses out from the DRG neurons or primary afferent terminals and stimulates guanylyl cyclase in neighboring DRG or dorsal horn neurons to form cyclic guanosine monophosphate (cGMP) . cGMP activates several intracellular processes, including cGMP-dependent protein kinase (PKG), ion channels, and phosphodiesterases (PDEs) . PKG is present in the small DRG neurons and the superficial dorsal horn [38, 39]. Sung et al.  showed that PKG was activated in peripheral terminals of the DRG neurons and retrogradely transported to the DRG after peripheral nerve injury and inflammation; however, intrathecal injection of a PKG inhibitor did not affect nerve injury-induced mechanical hypersensitivity . Interestingly, intraplantar injection of a PDE-5 inhibitor significantly reduced mechanical hypersensitivity in diabetic neuropathy. This effect could be reversed by inhibition of NOS and guanylyl cyclase . In addition, NO modulates the DRG Ca2+ and Na+ channels via cGMP-dependent pathways [43–45]. Therefore, it is very likely that DRG NOS-synthesized NO contributes to the mechanism that underlies the development and/or maintenance of neuropathic pain by activating PDEs and/or ion channels, but not by activating PKG, in the DRG and spinal cord.
In summary, we have provided genetic evidence that the deficiency of nNOS protein impairs mechanical hypersensitivity during the development and maintenance of neuropathic pain. Pharmacologic studies further demonstrated that systemic or spinal administration of specific and non-specific nNOS inhibitors attenuates nerve injury-induced mechanical hypersensitivity. Moreover, peripheral nerve injury up-regulates nNOS expression in the DRG but not in the spinal cord. These findings suggest that the DRG nNOS may play a role in the mechanism underlying neuropathic pain.
The nNOS knockout mice (C57BL/6J background) were purchased from Jackson Laboratories (Bar Harbor, ME, USA), cross-bred with C57BL/6J WT mice in our laboratory, and kept on a standard 12-h light/dark cycle, with water and food pellets available ad libitum. The genomic status of each mouse was checked with the use of reverse transcriptase-PCR and Western blotting . Male and female nNOS knockout mice are viable and fertile with normal appearance, as described before [5, 46]. Male mice weighing 25–30 g were used, and the WT littermates were used as controls. To minimize intra- and inter-individual variability of behavioral outcome measures, animals were trained for 1–2 days before behavioral testing was performed. Animal experiments were conducted with the approval of the Animal Care and Use Committee at Johns Hopkins University and were consistent with the ethical guidelines of the National Institutes of Health and the International Association for the Study of Pain. All efforts were made to minimize animal suffering and to reduce the number of animals used.
L-NAME and D-NG-nitro-arginine methyl ester (D-NAME) were purchased from Alexis Biochemicals (San Diego, CA, USA). 7-NI was purchased from Calbiochem Biosciences (La Jolla, CA, USA). 7-NI was dissolved in 20% dimethylsulfoxide (DMSO); all other drugs were dissolved in saline.
Intrathecal injection was performed under brief isoflurane (1.5%) anesthesia to reduce stress, as described previously . Briefly, a 30-gauge, 0.5-inch needle connected to a 10-μl syringe was inserted into one side of the L5 or L6 spinous process at an angle of approximately 20° above the vertebral column and slipped into the groove between the spinous and transverse processes. While the angle of the syringe was decreased to approximately 10°, the needle was moved carefully forward to the intervertebral space. A tail flick indicated that the tip of the needle was inserted into the subarachnoid space. Total volume of the injected solution was 5 μl. Mice were completely recovered (that is, were spontaneously active) within 3–5 min after injection.
Spinal nerve injury-induced neuropathic pain model in mice
The spinal nerve injury model was produced in mice as described previously . In brief, the mice were anesthetized with isoflurane and placed in a prone position. The left paraspinal muscles were separated from the spinous processes at the L4-S2 levels under aseptic conditions, and the left L5 spinal nerve was isolated, tightly ligated with a silk thread (7-0), and transected just distal to the ligature. In a control sham group, the surgical procedure was identical to that described above, except that the left L5 spinal nerve was not ligated and transected. The mice were returned to their cages and observed for any signs of motor deficits. None of the mice showed motor dysfunction after surgery. Behavioral tests described below were performed 1 day before spinal nerve injury and 3, 5, 7, 9, 13, and 17 days after spinal nerve injury.
To examine the effects of systemic administration of NOS inhibitors on the maintenance of L5 spinal nerve injury-induced mechanical hypersensitivity, WT mice received intraperitoneal injection of L-NAME (100 mg/kg), D-NAME (100 mg/kg), or saline on day 7 after spinal nerve injury. To further define the role of NOS at the spinal cord level in spinal nerve injury-induced mechanical hypersensitivity, the WT mice received an intrathecal injection of L-NAME (30 μg/5 μl), D-NAME (30 μg/5 μl), 7-NI (8.15 μg/5 μl), or vehicle (20% DMSO or saline, 5 μl) on day 7 after spinal nerve injury. Behavioral tests were performed as described below 1 day before spinal nerve injury, 1 h before drug administration, and 20 min after drug administration on day 7 post-nerve injury. The doses and duration of drug administration were based on our previous studies and those of others [5, 14, 47, 48].
To measure paw withdrawal responses to repeated mechanical stimuli, each mouse was placed in a Plexiglas chamber on an elevated mesh screen. Two calibrated von Frey monofilaments (0.24 and 4.33 mN; Stoelting Co., Wood Dale, IL, USA) were used. Each von Frey filament was applied to the hind paw for approximately 1 sec, and each stimulation was repeated 10 times to both hind paws. The occurrence of paw withdrawal in each of these 10 trials was expressed as a percent response frequency [(number of paw withdrawals/10 trials) × 100 = % response frequency], and this percentage was used as an indication of the amount of paw withdrawal. Experimenters were blinded to mouse genotype and drug assignment.
Western blot analysis
WT mice were sacrificed by decapitation on day 7 after spinal nerve injury or sham surgery. Naïve mice were used as controls. The fourth and fifth lumbar ipsilateral and contralateral DRGs and spinal dorsal horns were removed. All tissues were quickly frozen in liquid nitrogen and stored at -80°C for later use. Because of the small size of the unilateral fifth DRG and dorsal horn, the DRGs from four mice and dorsal horns from two mice were pooled together to obtain enough protein for Western blot analysis. Frozen tissues were homogenized in buffer (10 mM Tris-HCl, 5 mM MgCl2, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 1 μM leupeptin, 2 μM pepstatin A, 1 mM dithiothreitol). The crude homogenate was centrifuged at 4°C for 15 min at 700 × g. The supernatants (100 μg) were heated for 5 min at 98°C and then loaded onto 4% stacking/7.5% separating SDS-polyacrylamide gels. The proteins were electrophoretically transferred onto nitrocellulose membrane, blocked with 3% nonfat dry milk, and subsequently incubated overnight at 4°C with polyclonal rabbit anti-nNOS antibody (1:1,000, BD Transduction Laboratories, San Diego, CA, USA), polyclonal rabbit anti-eNOS antibody (1:1,000, BD Transduction), polyclonal rabbit anti-iNOS antibody (1:1,000, BD Transduction), or monoclonal mouse anti-β-actin antibody (1:3,000, Sigma, St. Louis, MO, USA). β-actin was used as a loading control. The proteins were detected with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies and visualized by chemiluminescence reagents provided with the ECL kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and exposure to film. The intensity of blots was quantified with densitometry. The blot density from the contralateral DRG or dorsal horn in the naïve mice was set as 100%. The relative density values of the ipsilateral DRG or dorsal horn in the naïve mice and from ipsilateral or contralateral DRG or dorsal horn in the spinal nerve-injured or sham-operated group were determined by dividing the optical density values from these groups by a value from the contralateral DRG or dorsal horn in the naïve mice.
Data from the behavioral tests and Western blots were expressed as mean ± SEM and analyzed with a one-way or two-way analysis of variance (ANOVA). When ANOVA showed significant differences, pairwise comparisons between means were tested by the post hoc Tukey method. A pairwise t-test was used to determine the significant differences of means for comparisons between two groups. Significance was set at P < 0.05. All statistical analyses were performed using the SigmaStat statistical software.
This work was supported by the NIH grant RO1 NS058886 (Y-X Tao), Blaustein Pain Research Fund (Y-X Tao), and Department of Anesthesiology at the Johns Hopkins University. The authors would like to thank Tzipora Sofare, MA, and Claire Levine, MS, for their editorial assistance.
- Snyder SH: Nitric oxide: first in a new class of neurotransmitters. Science 1992,257(5069):494–496. 10.1126/science.1353273PubMedView ArticleGoogle Scholar
- Meller ST, Gebhart GF: Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 1993, 52: 127–136. 10.1016/0304-3959(93)90124-8PubMedView ArticleGoogle Scholar
- Prast H, Philippu A: Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001, 64: 51–68. 10.1016/S0301-0082(00)00044-7PubMedView ArticleGoogle Scholar
- Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A: Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003,21(2):379–86. 10.1097/00004872-200302000-00030PubMedView ArticleGoogle Scholar
- Chu YC, Guan Y, Skinner J, Raja SN, Johns RA, Tao Y-X: Effect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent pain. Pain 2005, 119: 113–123. 10.1016/j.pain.2005.09.024PubMedView ArticleGoogle Scholar
- Tang Q, Svensson CI, Fitzsimmons B, Webb M, Yaksh TL, Hua XY: Inhibition of spinal constitutive NOS-2 by 1400W attenuates tissue injury and inflammation-induced hyperalgesia and spinal p38 activation. Eur J Neurosci 2007,25(10):I2964-I2972. 10.1111/j.1460-9568.2007.05576.xView ArticleGoogle Scholar
- Herdegen T, Rudiger S, Mayer B, Bravo R, Zimmermann M: Expression of nitric oxide synthase and colocalisation with Jun, Fos and Krox transcription factors in spinal cord neurons following noxious stimulation of the rat hindpaw. Brain Res Mol Brain Res 1994, 22: 245–258. 10.1016/0169-328X(94)90053-1PubMedView ArticleGoogle Scholar
- Lam HH, Hanley DF, Trapp BD, Saito S, Raja S, Dawson TM, Yamaguchi H: Induction of spinal cord neuronal nitric oxide synthase (NOS) after formalin injection in the rat hind paw. Neurosci Lett 1996, 210: 201–204. 10.1016/0304-3940(96)12702-6PubMedView ArticleGoogle Scholar
- Pozza M, Bettelli C, Magnani F, Mascia MT, Manzini E, Calzà L: Is neuronal nitric oxide involved in adjuvant-induced joint inflammation? Eur J Pharmacol 1998, 359: 87–93. 10.1016/S0014-2999(98)00618-9PubMedView ArticleGoogle Scholar
- Malmberg AB, Yaksh TL: Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993, 54: 291–300. 10.1016/0304-3959(93)90028-NPubMedView ArticleGoogle Scholar
- Roche AK, Cook M, Wilcox GL, Kajander KC: A nitric oxide synthesis inhibitor (L-NAME) reduces licking behavior and Fos-labeling in the spinal cord of rats during formalin-induced inflammation. Pain 1996, 66: 331–341. 10.1016/0304-3959(96)03025-4PubMedView ArticleGoogle Scholar
- Lawand NB, Willis WD, Westlund KN: Blockade of joint inflammation and secondary hyperalgesia by L-NAME, a nitric oxide synthase inhibitor. NeuroReport 1997, 8: 895–899. 10.1097/00001756-199703030-00016PubMedView ArticleGoogle Scholar
- Handy RLC, Moore PK: Effects of selective inhibitors of neuronal nitric oxide synthase on carrageenan-induced mechanical and thermal hyperalgesia. Neuropharmacology 1998, 37: 37–43. 10.1016/S0028-3908(97)00201-3PubMedView ArticleGoogle Scholar
- Osborne MG, Coderre TJ: Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Br J Pharmacol 1999,126(8):1840–1846. 10.1038/sj.bjp.0702508PubMed CentralPubMedView ArticleGoogle Scholar
- Tao F, Tao Y-X, Zhao C, Dore S, Liaw W-J, Raja SN, Johns RA: Differential roles of neuronal and endothelial nitric oxide synthases during carrageenan-induced inflammatory hyperalgesia. Neuroscience 2004, 128: 421–430. 10.1016/j.neuroscience.2004.06.038PubMedView ArticleGoogle Scholar
- Crosby G, Marota JJ, Huang PL: Intact nociception-induced neuroplasticity in transgenic mice deficient in neuronal nitric oxide synthase. Neuroscience 1995, 69: 1013–1017. 10.1016/0306-4522(95)00395-YPubMedView ArticleGoogle Scholar
- Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98: 585–598. 10.1016/S0306-4522(00)00110-XPubMedView ArticleGoogle Scholar
- Dubner R, Basbaum AI: In The Textbook of Pain. Wall PD, Melzack R edition. Churchill-Livingstone, London; 1994:225–241.Google Scholar
- Luo ZD, Chaplan SR, Scott BP, Cizkova D, Calcutt NA, Yaksh TL: Neuronal nitric oxide synthase mRNA upregulation in rat sensory neurons after spinal nerve ligation: Lack of a role in allodynia development. J Neurosci 1999, 19: 9201–9208.PubMedGoogle Scholar
- Cizkova D, Lukacova N, Marsala M, Marsala J: Neuropathic pain is associated with alterations of nitric oxide synthase immunoreactivity and catalytic activity in dorsal root ganglia and spinal dorsal horn. Brain Res Bull 2002, 58: 161–171. 10.1016/S0361-9230(02)00761-XPubMedView ArticleGoogle Scholar
- Ma W, Eisenach JC: Neuronal nitric oxide synthase is upregulated in a subset of primary sensory afferents after nerve injury which are necessary for analgesia from alpha2-adrenoceptor stimulation. Brain Res 2007,1127(1):52–8. 10.1016/j.brainres.2006.10.008PubMed CentralPubMedView ArticleGoogle Scholar
- Choi Y, Raja SN, Moore LC, Tobin JR: Neuropathic pain in rats is associated with altered nitric oxide synthase activity in neural tissue. J Neurol Sci 1996,138(1–2):14–20. 10.1016/0022-510X(95)00325-VPubMedView ArticleGoogle Scholar
- Hao JX, Xu XJ: Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered nitric oxide synthase inhibitors. Pain 1996, 66: 313–319. 10.1016/0304-3959(96)03039-4PubMedView ArticleGoogle Scholar
- Meller ST, Pechman PS, Gebhart GF, Maves TJ: Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience 1992, 50: 7–10. 10.1016/0306-4522(92)90377-EPubMedView ArticleGoogle Scholar
- Khalil Z, Khodr B: A role for free radicals and nitric oxide in delayed recovery in aged rats with chronic constriction nerve injury. Free Radic Biol Med 2001,31(4):430–9. 10.1016/S0891-5849(01)00597-4PubMedView ArticleGoogle Scholar
- Yoon YW, Sung B, Chung JM: Nitric oxide mediates behavioral signs of neuropathic pain in an experimental rat model. NeuroReport 1998, 9: 367–372. 10.1097/00001756-199802160-00002PubMedView ArticleGoogle Scholar
- Yamamoto T, Shimoyama N: Role of nitric oxide in the development of thermal hyperesthesia induced by sciatic nerve constriction injury in the rat. Anesthesiology 1995, 82: 1266–1273. 10.1097/00000542-199505000-00022PubMedView ArticleGoogle Scholar
- Pan HL, Chen SR, Eisenach JC: Role of spinal NO in antiallodynic effect of intrathecal clonidine in neuropathic rats. Anesthesiology 1998,89(6):1518–23. 10.1097/00000542-199812000-00031PubMedView ArticleGoogle Scholar
- Tao Y-X, Rumbaugh G, Wang GD, Petralia RS, Zhao C, Kauer FW, Tao F, Zhuo M, Wenthold RJ, Raja SN, Huganir RL, Bredt DS, Johns RA: Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein. J Neurosci 2003, 23: 6703–6712.PubMedGoogle Scholar
- Zhang B, Tao F, Liaw WJ, Bredt DS, Johns RA, Tao Y-X: Effect of knock down of spinal cord PSD-93/chapsin-110 on persistent pain induced by complete Freund's adjuvant and peripheral nerve injury. Pain 2003, 106: 187–196. 10.1016/j.pain.2003.08.003PubMedView ArticleGoogle Scholar
- Butler M, Hayes CS, Chappell A, Murray SF, Yaksh TL, Hua XY: Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience 2005,131(3):705–15. 10.1016/j.neuroscience.2004.11.038PubMedView ArticleGoogle Scholar
- Wu J, Lin Q, Lu Y, Willis WD, Westlund KN: Changes in nitric oxide synthase isoforms in the spinal cord of rat following induction of chronic arthritis. Exp Brain Res 1998, 118: 457–65. 10.1007/s002210050302PubMedView ArticleGoogle Scholar
- Levy D, Zochodne DW: Local nitric oxide synthase activity in a model of neuropathic pain. Eur J Neurosci 1998,10(5):1846–55. 10.1046/j.1460-9568.1998.00186.xPubMedView ArticleGoogle Scholar
- Levy D, Höke A, Zochodne DW: Local expression of inducible nitric oxide synthase in an animal model of neuropathic pain. Neurosci Lett 1999,260(3):207–9. 10.1016/S0304-3940(98)00982-3PubMedView ArticleGoogle Scholar
- Levy D, Kubes P, Zochodne DW: Delayed peripheral nerve degeneration, regeneration, and pain in mice lacking inducible nitric oxide synthase. J Neuropathol Exp Neurol 2001,60(5):411–421.PubMedGoogle Scholar
- De Alba J, Clayton NM, Collins SD, Colthup P, Chessell I, Knowles RG: GW27 a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain 2006,120(1–2):170–81. 10.1016/j.pain.2005.10.028PubMedView ArticleGoogle Scholar
- Knowles RG, Palacios M, Palmer RM, Moncada S: Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci USA 1989,86(13):5159–62. 10.1073/pnas.86.13.5159PubMed CentralPubMedView ArticleGoogle Scholar
- Tao YX, Hassan A, Haddad E, Johns RA: Expression and action of cyclic GMP-dependent protein kinase Ialpha in inflammatory hyperalgesia in rat spinal cord. Neuroscience 2000, 95: 525–33. 10.1016/S0306-4522(99)00438-8PubMedView ArticleGoogle Scholar
- Qian Y, Chao DS, Santillano DR, Cornwell TL, Nairn AC, Greengard P, Lincoln TM, Bredt DS: cGMP-dependent protein kinase in dorsal root ganglion: relationship with nitric oxide synthase and nociceptive neurons. J Neurosci 1996,16(10):3130–8.PubMedGoogle Scholar
- Sung YJ, Chiu DT, Ambron RT: Activation and retrograde transport of protein kinase G in rat nociceptive neurons after nerve injury and inflammation. Neuroscience 2006,141(2):697–709. 10.1016/j.neuroscience.2006.04.033PubMedView ArticleGoogle Scholar
- Hua XY, Chen P, Yaksh TL: Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats. Neurosci Lett 1999,276(2):99–102. 10.1016/S0304-3940(99)00818-6PubMedView ArticleGoogle Scholar
- Patil CS, Singh VP, Singh S, Kulkarni SK: Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. Pharmacology 2004,72(3):190–5. 10.1159/000080104PubMedView ArticleGoogle Scholar
- Kim SJ, Song SK, Kim J: Inhibitory effect of nitric oxide on voltage-dependent calcium currents in rat dorsal root ganglion cells. Biochem Biophys Res Commun 2000,271(2):509–14. 10.1006/bbrc.2000.2658PubMedView ArticleGoogle Scholar
- Yoshimura N, Seki S, de Groat WC: Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 2001,86(1):304–11.PubMedGoogle Scholar
- Renganathan M, Cummins TR, Waxman SG: Nitric oxide blocks fast, slow, and persistent Na+ channels in C-type DRG neurons by S-nitrosylation. J Neurophysiol 2002,87(2):761–75.PubMedGoogle Scholar
- Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC: Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993, 75: 1273–1286. 10.1016/0092-8674(93)90615-WPubMedView ArticleGoogle Scholar
- Zajac JM, Latapie JP, Frances B: Opposing interplay between Neuropeptide FF and nitric oxide in antinociception and hypothermia. Peptides 2000, 21: 1209–1213. 10.1016/S0196-9781(00)00261-8PubMedView ArticleGoogle Scholar
- Bulutcu F, Dogrul A, Guc MO: The involvement of nitric oxide in the analgesic effects of ketamine. Life Sci 2002, 71: 841–853. 10.1016/S0024-3205(02)01765-4PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.